Terray Therapeutics and BMS Sign a Multi-Target Collaboration Agreement for the Discovery and Development of Small Molecules
Shots:
- As per the agreement, Terray will discover and develop small molecules by employing its tNova platform against a set of targets identified by BMS while BMS has the development and commercialization rights
- Terray is entitled to an upfront payment, milestone payments linked to preclinical, clinical & sales achievements as well as tiered royalties based on the global net sales of products
- Terray's tNova platform is an AI-based drug discovery, integrating chemical experimentation and computation which generates extensive, purpose-built data to optimize small molecules, aiming to find precise solutions for complex issues in drug discovery
Ref: BMS | Image: BMS
Related News:- BMS Collaborates with Systimmune and Entered into An Exclusive License Agreement For the Development of BL-B01D1
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
